Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBritish Columbia Cancer Agency

About this trial

Researchers are looking for better ways of understanding and treating pancreatic cancer. The purpose of this study is to see how useful it is to look for changes and characteristics in your genes (molecules that contain instructions for the development and functioning of the cells) and the genes within the tumour. These characteristics may be useful in choosing treatments for patients in the future. Changes (mutations) in genes have been shown to be an important characteristic in cancers. Looking at differences in genes in patients with advanced pancreatic ductal adenocarcinomas and comparing this information with response to their initial chemotherapy treatment may help to learn which treatments may be better for certain patients after initial treatment.

Eligibility criteria

Qualifiers

Histological and/or radiological diagnosis of metastatic PDAC. Patients without a histological diagnosis of PDAC must undergo confirmatory tumour biopsy prior to treatment start date.

Planned for first-line systemic therapy with FOLFIRINOX or GP, either in routine care or in combination with an investigational agent(s) within a clinical trial.

Age ≥ 18 years

Eastern Cooperative Oncology Group (ECOG) performance status 0-1

Disqualifiers

Absence of distant or lymph node metastases. Patients with borderline resectable or locally advanced PDAC are not eligible.

Received prior systemic therapy (chemotherapy or any other anti-cancer agent) in the advanced setting. Patients who received adjuvant chemotherapy after surgical resection of early stage disease are eligible.

Currently receiving anti-cancer therapy (chemotherapy or any other anti-cancer agent)

Not fit for combination chemotherapy as judged by the investigator

Trial design

Treatments tested in this trial

  • Tumour Biopsy
  • Serial Collection of Plasma and Serum Samples

Treatment groups

190 Participants
are divided into 2 treatment groups

Sponsors and collaborators

British Columbia Cancer Agency

Lead sponsor

Terry Fox Research Institute

Collaborator

BC Cancer Foundation

Collaborator

Pancreas Centre BC

Collaborator

American Society of Clinical Oncology

Collaborator